Menu
Recruiting NCT07010094

BM Shockwave Devices Clinical Study in Coronary Calcified Lesions

No phase Interventional Coronary Artery Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: BM shockwave devices.
Who it may be relevant to
Registry conditions: Coronary Artery Disease. Basic parameters: 18 years — 85 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Prospective, Multicenter, Single-arm, Target-Value Clinical Trial to Evaluate the Safety and Efficacy of BM Shockwave Devices to Treat Coronary Calcified Lesions

Overview

This clinical trial is a prospective, multicenter, single-arm, target-value study to verify the safety and efficacy of BM coronary shockwave devices for the treatment of coronary calcification lesions.

Interventions

  • Device BM shockwave devices
    Use the BM shockwave devices for pre-treatment of coronary calcification lesions.

Primary outcome measures

  • Procedure success rate [Time frame: Endpoints will be measured through hospital discharge (expected to be within 7 days)]
Secondary outcome measures (6)
  • Angiography success rate [Time frame: 0 day]
  • Device success rate [Time frame: 0 day]
  • Residual stenosis [Time frame: 0 day]
  • MACE rate [Time frame: 30 days]
  • Target lesion failure [Time frame: 30 days]
  • Device defects [Time frame: 0 day]

Eligibility criteria

Inclusion criteria

  • General inclusion criteria:
  • Age 18-85 years, male or female;
  • Patients with evidence of asymptomatic ischemia, stable or unstable angina, or old myocardial infarction;
  • Patient is able and willing to comply with all assessments in the study.

Angiography inclusion criteria:

  • The target lesion is a de novo, in-situ coronary artery lesion;
  • The target lesion length is ≤40 mm, and the target lesion reference vessel diameter is 2.0-4.0 mm (visual estimation);
  • The target lesion diameter stenosis is visually estimated to be ≥70%, or <70% but ≥50% with evidence of ischemia;
  • Clear high-density calcification shadows are visible both during cardiac contraction and at rest;
  • Target vessel TIMI flow grade 3 prior to use of the investigational device (pre-dilatation is permitted);
  • The target lesion is the only calcified lesion to be treated with shock wave therapy in this session; if non-target lesions are present, they must be successfully treated prior to the target lesion;
  • Patients suitable for treatment with metal stent implantation.

Exclusion criteria

  • General exclusion criteria:
  • ST-segment elevation myocardial infarction within 3 days prior to the procedure;
  • Use of rotational atherectomy or special balloons (chocolate balloon, scoring balloon, cutting balloon, etc.) for lesion pretreatment;
  • New York Heart Association (NYHA) functional class III or IV;
  • Target lesion expected to require full biodegradable scaffold implantation, drug-eluting balloon dilation, or percutaneous transluminal coronary angioplasty (PTCA) treatment;
  • Uncontrolled severe hypertension (persistent: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg);
  • Severe liver or kidney dysfunction, with transaminase levels exceeding three times the upper limit of normal, serum creatinine >2.5 mg/dL (221 μmol/L), or chronic kidney failure requiring long-term dialysis;
  • Platelet count <60 × 10⁹/L;
  • Stroke within the past 6 months prior to enrollment, excluding transient ischemic attack (TIA) and lacunar infarction;
  • Active peptic ulcer or history of upper gastrointestinal bleeding within the past 6 months prior to enrollment;
  • Known allergy to heparin, contrast agents, aspirin, clopidogrel, or anesthetics;
  • Patients with a life expectancy of less than 12 months due to severe medical conditions;
  • Patients who have participated in other drug or device clinical trials and failed to meet the primary endpoint;
  • Pregnant or breastfeeding women;
  • Patients deemed by the investigator to have poor compliance and unable to complete the study according to the protocol.

Contrast exclusion criteria:

  • The target lesion and non-target lesion are in the same vascular branch;
  • The target lesion is at the origin (LAD, LCX, or RCA, within 5 mm of the origin) or an unprotected left main lesion;
  • A stent has been implanted within 10 mm of the proximal or distal end of the target lesion;
  • The target lesion has an unprotected branch vessel with a diameter of 2.5 mm or greater;
  • The target lesion is located distal to the saphenous vein or LIMA (left internal mammary artery)/RIMA (right internal mammary artery) bypass graft;
  • An aneurysm is present within 10 mm of the target lesion;
  • Contrast imaging confirms the presence of an NHLBI classification D-F type arterial dissection at the target lesion prior to the use of the investigational device;
  • The target lesion has definite thrombus formation;
  • The investigator determines that the target lesion is not suitable for vascular dilation in the patient.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Xiamen University Affiliated Cardiovascular Hospital — Fujian

Identifiers

NCT: NCT07010094 · D24

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗